Market closedNon-fractional
Beam Therapeutics/BEAM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Beam Therapeutics
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
Ticker
BEAM
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
346
Website
beamtx.com
BEAM Metrics
BasicAdvanced
$2.5B
Market cap
-
P/E ratio
-$1.69
EPS
1.87
Beta
-
Dividend rate
Price and volume
Market cap
$2.5B
Beta
1.87
Financial strength
Current ratio
5.991
Quick ratio
5.846
Long term debt to equity
17.071
Total debt to equity
18.404
Management effectiveness
Return on assets (TTM)
-8.44%
Return on equity (TTM)
-16.09%
Valuation
Price to revenue (TTM)
7.087
Price to book
2.77
Price to tangible book (TTM)
2.77
Price to free cash flow (TTM)
-15.11
Growth
Revenue change (TTM)
370.57%
Earnings per share change (TTM)
-62.01%
3-year revenue growth (CAGR)
2,368.29%
3-year earnings per share growth (CAGR)
-36.94%
What the Analysts think about BEAM
Analyst Ratings
Majority rating from 15 analysts.
BEAM Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$7.4M
-97.66%
Net income
-$99M
-169.10%
Profit margin
-1,332.43%
-3,051.77%
BEAM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.08
-$1.22
$1.73
-$1.21
-
Expected
-$1.42
-$1.36
-$1.01
-$1.42
-$1.14
Surprise
-24.19%
-10.40%
-271.08%
-14.63%
-
BEAM News
AllArticlesVideos
Beam Therapeutics Announces Transition of Chief Financial Officer
GlobeNewsWire·2 weeks ago
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
GlobeNewsWire·1 month ago
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Beam Therapeutics stock?
Beam Therapeutics (BEAM) has a market cap of $2.5B as of July 27, 2024.
What is the P/E ratio for Beam Therapeutics stock?
The price to earnings (P/E) ratio for Beam Therapeutics (BEAM) stock is 0 as of July 27, 2024.
Does Beam Therapeutics stock pay dividends?
No, Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Beam Therapeutics dividend payment date?
Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders.
What is the beta indicator for Beam Therapeutics?
Beam Therapeutics (BEAM) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Beam Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.